Compass Therapeutics, Inc.(CMPX)

Biotechnology · Boston, MA

$1.01+0.04 (+4.62%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T18:50:57.748Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:50:57.748Z.

Quote observation: 2026-10-06T18:50:08.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 1.005
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.415

FMP input reference: 273f4a35489c6dcba82bfbf6813c8f243fa8fa5e32baf23fc33ea9a1b57f5f97

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

CMPX PE Ratio Metrics

PE RATIO

N/A

CMPX Competitors' PE Ratio

CMPX

Compass Therapeutics, Inc.

Current

Market Cap

$180.99M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs CMPX

Market Cap

$181.30M

PE Ratio

1.08

TTM Avg

2.35

3Y Avg

8.36

5Y Avg

8.36

CNTN

Canton Strategic Holdings Inc

vs CMPX

Market Cap

$183.17M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANTX

AN2 Therapeutics, Inc.

vs CMPX

Market Cap

$184.04M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

YARW

Yarrow Bioscience Inc

vs CMPX

Market Cap

$178.83M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRQR

ProQR Therapeutics N.V.

vs CMPX

Market Cap

$173.76M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs CMPX

Market Cap

$189.50M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DERM

Journey Medical Corporation

vs CMPX

Market Cap

$173.94M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXST

RxSight, Inc.

vs CMPX

Market Cap

$191.67M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DTIL

Precision BioSciences, Inc.

vs CMPX

Market Cap

$171.13M

PE Ratio

N/A

TTM Avg

11.57

3Y Avg

11.57

5Y Avg

11.57

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Compass Therapeutics, Inc. (CMPX)	$180.99M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$181.30M	1.08	2.35	8.36	8.36
Canton Strategic Holdings Inc (CNTN)vs ›	$183.17M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$184.04M	N/A	N/A	N/A	N/A
Yarrow Bioscience Inc (YARW)vs ›	$178.83M	N/A	N/A	N/A	N/A
ProQR Therapeutics N.V. (PRQR)vs ›	$173.76M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$189.50M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$173.94M	N/A	N/A	N/A	N/A
RxSight, Inc. (RXST)vs ›	$191.67M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$171.13M	N/A	11.57	11.57	11.57

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$1.00

Forward EPS (Est.)

$-0.50

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.

Boston, MA

39 employees

www.compasstherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Thomas J. Schuetz

View full financials

NAME

MARKET CAP

PE RATIO

TTM

Compass Therapeutics, Inc. (CMPX)

$180.99M

N/A

Oramed Pharmaceuticals Inc. (ORMP)vs ›

$181.30M

1.08

2.35

8.36

Canton Strategic Holdings Inc (CNTN)vs ›

$183.17M

N/A

AN2 Therapeutics, Inc. (ANTX)vs ›

$184.04M

N/A

Yarrow Bioscience Inc (YARW)vs ›

$178.83M

N/A

ProQR Therapeutics N.V. (PRQR)vs ›

$173.76M

N/A

Eledon Pharmaceuticals, Inc. (ELDN)vs ›

$189.50M

N/A

Journey Medical Corporation (DERM)vs ›

$173.94M

N/A

RxSight, Inc. (RXST)vs ›

$191.67M

N/A

Precision BioSciences, Inc. (DTIL)vs ›

$171.13M

N/A

11.57

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

CMPX PE Ratio Metrics

CMPX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics

PE Ratio: N/A

CMPX PE Ratio Metrics

CMPX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics